言語を選択

VEGF-B

VEGF-B 詳細

英語名	Vascular endothelial growth factor B	市販薬剤の数	1
治験薬の数	4	ターゲットの別称	VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
研究＆開発段階	Approved

英語名	Vascular endothelial growth factor B
ターゲットの別称	VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
市販薬剤の数	1
治験薬の数	4
研究＆開発段階	Approved

VEGF-B 製品リスト

属性
Protein (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
His Tag (1)
マーカー
Unconjugated (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
VE6-H5225	Human	HEK293	Human VEGF-B Protein, His Tag

総数量1

VEGF-Bバックグランド

Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.

VEGF-B分子の別称

VRF,VEGFL,VEGFB,VEGF-B

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
4D-150	4D-150	Phase 3 Clinical	4d Molecular Therapeutics Inc	Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration	詳細
Reflocibart	2H-10; CSL-346	Phase 2 Clinical	Csl Ltd	Diabetic Nephropathies	詳細
PB-101	PB-101	Phase 1 Clinical	Panolos Bioscience Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms	詳細
EB-105	EB-105	Phase 1 Clinical	Eluminex Biosciences (Suzhou) Ltd	Diabetic macular oedema; Diabetic Retinopathy	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Ziv-aflibercept	AVE-0005; BAY-865321	Approved	Regeneron Pharmaceuticals Inc, Sanofi	Zaltrap	United States	Colorectal Neoplasms	Sanofi-Aventis U.S. Llc	2012-08-03	Adenocarcinoma, Follicular; Ascites; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Gliosarcoma; Leiomyosarcoma; Leukemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Lung Diseases; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 1; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Retinal Vein Occlusion; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid	詳細